Novel insights on imaging sex hormone-dependent tumourigenesis in vivo

Endocrine-Related Cancer

Volumn 18, Issue 3, 2011, Pages

  Ramachandran, Balaji ^a   Stell, Alessia ^a   Maravigna, Luca ^a   Maggi, Adriana ^a   Ciana, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; GONADORELIN DERIVATIVE; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; SEX HORMONE; STEROID HORMONE; STEROID RECEPTOR; TRANSCRIPTION FACTOR GAL4;

ANGIOGENESIS; APOPTOSIS; BACTERIAL ARTIFICIAL CHROMOSOME; BIOLUMINESCENCE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CARCINOGENESIS; CELL MIGRATION; DNA RESPONSIVE ELEMENT; ENDOCRINE TUMOR; GENETIC TRANSCRIPTION; HORMONE SYNTHESIS; HUMAN; HYDROPHOBICITY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIGAND BINDING; METASTASIS; MOLECULAR IMAGING; NONHUMAN; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ULTRASOUND;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GONADAL STEROID HORMONES; LUMINESCENT PROTEINS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 79960101745     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0332     Document Type: Review

References (105)

1. Alarid ET 2006 Lives and times of nuclear receptors. Molecular Endocrinology 20 1972-1981. (doi:10.1210/me.2005-0481)
2. Anderson E 2002 The role of oestrogen and progesterone receptors in human mammary development and tumourigenesis. Breast Cancer Research 4 197-201. (doi:10.1186/bcr452)
3. Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, Tangerud A & Tobin D 2006 Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. Journal of Nuclear Medicine 47 1434-1439. (Pubitemid 47544928)
4. Beer AJ, Grosu A-L, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester H-J, Haubner R & Schwaiger M 2007 [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clinical Cancer Research 13 6610-6616. (doi:10.1158/1078-0432.CCR-07-0528)
5. Bilińska B, Wiszniewska B, Kosiniak-Kamysz K, Kotula-Balak M, Gancarczyk M, Hejmej A, Sadowska J, Marchlewicz M, Kolasa A & Wenda-Rózewicka L 2006 Hormonal status of male reproductive system: androgens and estrogens in the testis and epididymis. In vivo and in vitro approaches. Reproductive Biology 6 43-58.
6. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, Conti G, Cruciani G, Dammino S, Delliponti U et al. 1999 Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. Journal of Clinical Oncology 17 2027-2038. (Pubitemid 29318831)
7. Bogin L & Degani H 2002 Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Research 62 1948-1951. (Pubitemid 34408435)
8. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J & Perrot-Applanat M 2002 Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Research 62 4977-4984. (Pubitemid 34984422)
9. Butt AJ, McNeil CM, Musgrove EA & Sutherland RL 2005 Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocrine-Related Cancer 12 S47-S59. (doi:10.1677/erc.1.00993)
10. Carruba G 2007 Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. Journal of Cellular Biochemistry 102 899-911. (doi:10.1002/jcb.21529)
11. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (doi:10.1038/nm972)
12. Cherry SR 2009 Multimodality imaging: beyond PET/CT and SPECT/CT. Seminars in Nuclear Medicine 39 348-353. (doi:10.1053/j.semnuclmed.2009.03.001)
13. Ciana P, Luccio GD, Belcredito S, Pollio G, Vegeto E, Tatangelo L, Tiveron C & Maggi A 2001 Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Molecular Endocrinology 15 1104-1113. (doi:10.1210/me.15.7.1104)
14. Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, Parker MG, Lowik C & Maggi A 2003 In vivo imaging of transcriptionally active estrogen receptors. Nature Medicine 9 82-86. (doi:10.1038/nm809)
15. Ciana P, Brena A, Sparaciari P, Bonetti E, Lorenzo DD & Maggi A 2005 Estrogenic activities in rodent estrogenfree diets. Endocrinology 146 5144-5150. (doi:10.1210/en.2005-0660)
16. Clarke RB 2004 Human breast cell proliferation and its relationship to steroid receptor expression. Climacteric 7 129-137. (doi:10.1080/ 13697130410001713751)
17. Clarke RB, Howell A, Potten CS & Anderson E 1997 Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Research 57 4987-4991. (Pubitemid 27498105)
18. De S, Macara IG & Lannigan DA 2005 Novel biosensors for the detection of estrogen receptor ligands. Journal of Steroid Biochemistry and Molecular Biology 96 235-244. (doi:10.1016/j.jsbmb.2005.04.030)
19. Dondi D, Piccolella M, Biserni A, Torre SD, Ramachandran B, Locatelli A, Rusmini P, Sau D, Caruso D, Maggi A et al. 2010 Estrogen receptor beta and the progression of prostate cancer: role of 5alpha-androstane-3beta,17-beta-diol. Endocrine-Related Cancer 17 731-742. (doi:10.1677/ERC-10-0032)
20. Dunphy MPS & Lewis JS 2009 Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. Journal of Nuclear Medicine 50 106S-121S. (doi:10.2967/jnumed.108.057281)
21. Ellem SJ & Risbridger GP 2010 Aromatase and regulating the estrogen:androgen ratio in the prostate gland. Journal of Steroid Biochemistry and Molecular Biology 118 246-251. (doi:10.1016/j.jsbmb.2009.10.015)
22. Esteller M 2006 Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. British Journal of Cancer 94 179-183. (doi:10.1038/sj.bjc.6602918)
23. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK et al. 1998 Tumor induction of VEGF promoter activity in stromal cells. Cell 94 715-725. (doi:10.1016/S0092-8674(00)81731-6)
24. Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A, Martini PGV, Katzenellenbogen BS, Martini L, Motta Met al. 2005 The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Research 65 5445-5453. (doi:10.1158/0008-5472.CAN-04-1941)
25. Han SJ, Jeong J, Demayo FJ, Xu J, Tsai SY, Tsai M-J & O'Malley BW 2005 Dynamic cell type specificity of SRC-1 coactivator in modulating uterine progesterone receptor function in mice. Molecular and Cellular Biology 25 8150-8165. (doi:10.1128/MCB.25.18.8150-8165.2005)
26. Han SJ, O'Malley BW & DeMayo FJ 2009 An estrogen receptor alpha activity indicator model in mice. Genesis 47 815-824. (doi:10.1002/dvg.20572)
27. Hanahan D & Weinberg RA 2000 The hallmarks of cancer. Cell 100 57-70. (doi:10.1016/S0092-8674(00)81683-9)
28. Hirata S, Shoda T, Kato J & Hoshi K 2003 Isoform/variant mRNAs for sex steroid hormone receptors in humans. Trends in Endocrinology and Metabolism 14 124-129. (doi:10.1016/S1043-2760(03)00028-6)
29. Hong H, Yang Y, Zhang Y & Cai W 2010 Non-invasive cell tracking in cancer and cancer therapy. Current Topics in Medicinal Chemistry 10 1237-1248. (doi:10.2174/156802610791384234)
30. Hood JD & Cheresh DA 2002 Role of integrins in cell invasion and migration. Nature Reviews. Cancer 2 91-100. (doi:10.1038/nrc727)
31. Hospers GAP, Helmond FA, de Vries EGE, Dierckx RA & de Vries EFJ 2008 PET imaging of steroid receptor expression in breast and prostate cancer. Current Pharmaceutical Design 14 3020-3032. (doi:10.2174/138161208786404362)
32. Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK & Robertson JFR 2005 Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104 236-239. (doi:10.1002/cncr.21163)
33. Hsieh C-L, Xie Z, Liu Z-Y, Green JE, Martin WD, Datta MW, Yeung F, Pan D & Chung LWK 2005 A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals. Journal of Molecular Endocrinology 35 293-304. (doi:10.1677/jme.1.01722)
34. Hsieh C-L, Xie Z, Yu J, Martin WD, Datta MW, Wu G-J & Chung LWK 2007 Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model. Prostate 67 685-691. (doi:10.1002/pros. 20510)
35. Hu Z, Liang J, Yang W, Fan W, Li C, Ma X, Chen X, Ma X, Li X & Qu X 2010 Experimental Cerenkov luminescence tomography of the mouse model with SPECT imaging validation. Optics Express 18 24441-24450. (doi:10.1364/OE.18.024441)
36. Imamov O, Lopatkin NA & Gustafsson J-A 2004 Estrogen receptor beta in prostate cancer. New England Journal of Medicine 351 2773-2774. (doi:10.1056/NEJM200412233512622)
37. Jonson SD & Welch MJ 1998 PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Quarterly Journal of Nuclear Medicine 42 8-17. (Pubitemid 28244262)
38. Kaarbø M, Klokk TI & Saatcioglu F 2007 Androgen signalling and its interactions with other signalling pathways in prostate cancer. Bioessays 29 1227-1238. (doi:10.1002/bies.20676)
39. Katzenellenbogen JA, Senderoff SG, McElvany KD, O'Brien HA & Welch MJ 1981 16 alpha-[77Br]bromoestradiol-17 beta: a high specific-activity, gamma-emitting tracer with uptake in rat uterus and uterus and induced mammary tumours. Journal of Nuclear Medicine 22 42-47. (Pubitemid 11213144)
40. Katzenellenbogen JA, Welch MJ & Dehdashti F 1997 The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Research 17 1573-1576. (Pubitemid 27263124)
41. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S & Aboagye EO 2007 Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging 34 1339-1347. (doi:10.1007/s00259-007-0379-4)
42. Kesarwala AH, Prior JL, Sun J, Harpstrite SE, Sharma V & Piwnica-Worms D 2006 Second-generation triple reporter for bioluminescence, micro-positron emission tomography, and fluorescence imaging. Molecular Imaging 5 465-474. (Pubitemid 46142820)
43. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA & Welch MJ 1984 Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. Journal of Nuclear Medicine 25 1212-1221. (Pubitemid 15214135)
44. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA et al. 2007 Antitumour and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Research 67 9337-9345. (doi:10.1158/0008- 5472.CAN-06-4018)
45. Korpanty G, Carbon JG, Grayburn PA, Fleming JB & Brekken RA 2007 Monitoring response to anticancer therapy by targeting microbubbles to tumour vasculature. Clinical Cancer Research 13 323-330. (doi:10.1158/1078-0432.CCR-06- 1313)
46. 2). Nuclear Receptor Signaling 4 e021. (doi:10.1621/nrs.04021)
47. Kurihara H, Yang DJ, Cristofanilli M, Erwin WD, Yu D-F, Kohanim S, Mendez R & Kim EE 208 Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumours. Applied Radiation and Isotopes 66 1175-1182. (doi:10.1016/j.apradiso.2008.01.012)
48. Kuukasjärvi T, Kononen J, Helin H, Holli K & Isola J 1996 Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. Journal of Clinical Oncology 14 2584-2589. (Pubitemid 26300127)
49. Kwock L, Smith JK, Castillo M, Ewend MG, Collichio F, Morris DE, Bouldin TW & Cush S 2006 Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncology 7 859-868. (doi:10.1016/S1470-2045(06)70905-6)
50. LaMarca HL & Rosen JM 2008 Minireview: hormones and mammary cell fate - what will I become when I grow up? Endocrinology 149 4317-4321. (doi:10.1210/en.2008-0450)
51. Lamont KR & Tindall DJ 2010 Androgen regulation of gene expression. Advances in Cancer Research 107 137-162. (doi:10.1016/S0065-230X(10)07005-3)
52. Laprie A, Catalaa I, Cassol E, McKnight TR, Berchery D, Marre D, Bachaud J-M, Berry I & Moyal EC-J 2008 Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. International Journal of Radiation Oncology, Biology, Physics 70 773-781. (doi:10.1016/j. ijrobp.2007.10.039)
53. Lee S & Chen X 2009 Dual-modality probes for in vivo molecular imaging. Molecular Imaging 8 87-100.
54. Lemmen JG, Arends RJ, van Boxtel AL, van der Saag PT & van der Burg B 2004 Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. Journal of Molecular Endocrinology 32 689-701. (doi:10.1677/jme.0.0320689)
55. Lewis-Wambi JS & Jordan VC 2009 Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Research 11 206. (doi:10.1186/bcr2255)
56. Liu A, Carlson KE & Katzenellenbogen JA 1992 Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. Journal of Medicinal Chemistry 35 2113-2129. (doi:10.1021/jm00089a024)
57. Lyons SK, Lim E, Clermont AO, Dusich J, Zhu L, Campbell KD, Coffee RJ, Grass DS, Hunter J, Purchio T et al. 2006 Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice. Cancer Research 66 4701-4707. (doi:10.1158/0008-5472.CAN-05-3598)
58. Maggi A, Ottobrini L, Biserni A, Lucignani G & Ciana P 2004 Techniques: reporter mice - a new way to look at drug action. Trends in Pharmacological Sciences 25 337-342. (doi:10.1016/j.tips.2004.04.007)
59. Massoud TF & Gambhir SS 2003 Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes and Development 17 545-580. (doi:10.1101/gad.1047403)
60. Mata de Urquiza AM & Perlmann T 2003 In vivo and in vitro reporter systems for studying nuclear receptor and ligand activities. Methods in Enzymology 364 463-475. (doi:10.1016/S0076-6879(03)64026-7)
61. McElvany KD, Carlson KE, Welch MJ, Senderoff SG & Katzenellenbogen JA 1982 In vivo comparison of 16 alpha[77Br]bromoestradiol-17 beta and 16 alpha-[125I]iodoestradiol-17 beta. Journal of Nuclear Medicine 23 420-424.
62. Merlo LMF, Pepper JW, Reid BJ & Maley CC 2006 Cancer as an evolutionary and ecological process. Nature Reviews. Cancer 6 924-935. (doi:10.1038/nrc2013)
63. Michelini E, Mirasoli M, Karp M, Virta M & Roda A 2004 Development of a bioluminescence resonance energy-transfer assay for estrogen-like compound in vivo monitoring. Analytical Chemistry 76 7069-7076. (doi:10.1021/ac048914h)
64. Migliaccio A, Castoria G & Auricchio F 2007 Src-dependent signalling pathway regulation by sex-steroid hormones: therapeutic implications. International Journal of Biochemistry & Cell Biology 39 1343-1348. (doi:10.1016/j.biocel.2006.12.009)
65. Musgrove EA & Sutherland RL 2009 Biological determinants of endocrine resistance in breast cancer. Nature Reviews. Cancer 9 631-643. (doi:10.1038/nrc2713)
66. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR & de Hooge MNL 2007 In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumour xenograft. Journal of Nuclear Medicine 48 1313-1319. (doi:10.2967/jnumed.107.041301)
67. Ozers MS, Marks BD, Gowda K, Kupcho KR, Ervin KM, De Rosier T, Qadir N, Eliason HC, Riddle SM & Shekhani MS 2007 The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry 46 683-695. (doi:10.1021/bi061321b)
68. Paulmurugan R & Gambhir SS 2006 An intramolecular folding sensor for imaging estrogen receptor-ligand interactions. PNAS 103 15883-15888. (doi:10.1073/pnas.0607385103)
69. Paulmurugan R, Padmanabhan P, Ahn B-C, Ray S, Willmann JK, Massoud TF, Biswal S & Gambhir SS 2009 A novel estrogen receptor intramolecular folding-based titratable transgene expression system. Molecular Therapy 17 1703-1711. (doi:10.1038/mt.2009.171)
70. Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, Gown A, Link JM, Tewson T & Krohn KA 2008 Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. Journal of Nuclear Medicine 49 367-374. (doi:10.2967/jnumed.107.047506)
71. Pio BS, Park CK, Pietras R, Hsueh W-A, Satyamurthy N, Pegram MD, Czernin J, Phelps ME & Silverman DHS 2006 Usefulness of 3′-[F-18]fluoro- 3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Molecular Imaging and Biology 8 36-42. (doi:10.1007/s11307-005-0029-9)
72. Powell E & Xu W 2008 Intermolecular interactions identify ligand-selective activity of estrogen receptor alpha/beta dimers. PNAS 105 19012-19017. (doi:10.1073/pnas.0807274105)
73. Pysz MA, Gambhir SS & Willmann JK 2010 Molecular imaging: current status and emerging strategies. Clinical Radiology 65 500-516. (doi:10.1016/j.crad.2010.03.011)
74. Quignodon L, Legrand C, Allioli N, Guadaño-Ferraz A, Bernal J, Samarut J & Flamant F 2004 Thyroid hormone signalling is highly heterogeneous during pre- and postnatal brain development. Journal of Molecular Endocrinology 33 467-476. (doi:10.1677/jme.1.01570)
75. Rijks LJ, Sokole EB, Stabin MG, de Bruin K, Janssen AG & van Royen EA 1998 Biodistribution and dosimetry of iodine-123-labelled Z-MIVE: an oestrogen receptor radioligand for breast cancer imaging. European Journal of Nuclear Medicine 25 40-47. (Pubitemid 28107902)
76. Robertson R, Germanos MS, Li C, Mitchell GS, Cherry SR & Silva MD 2009 Optical imaging of Cerenkov light generation from positron-emitting radiotracers. Physics in Medicine and Biology 54 N355-N365. (doi:10.1088/0031- 9155/54/16/N01)
77. Ruggiero A, Holland JP, Lewis JS & Grimm J 2010 Cerenkov luminescence imaging of medical isotopes. Journal of Nuclear Medicine 51 1123-1130. (doi:10.2967/jnumed.110.076521)
78. Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A & Brodie AMH 2008 Stopping treatment can reverse acquired resistance to letrozole. Cancer Research 68 4518-4524. (doi:10.1158/0008-5472.CAN-07-5999)
79. Safran M, Kim WY, O'Connell F, Flippin L, Günzler V, Horner JW, Depinho RA & Kaelin WG Jr 2006 Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. PNAS 103 105-110. (doi:10.1073/pnas.0509459103)
80. Sarker D, Reid AHM, Yap TA & de Bono JS 2009 Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clinical Cancer Research 15 4799-4805. (doi:10.1158/1078-0432.CCR-08-0125)
81. Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y & Dahiya R 2003 Hypermethylation can selectively silence multiple promoters of steroid receptors in cancers. Molecular and Cellular Endocrinology 202 201-207. (doi:10.1016/S0303-7207(03)00084-4)
82. Sauter AW, Wehrl HF, Kolb A, Judenhofer MS & Pichler BJ 2010 Combined PET/MRI: one step further in multimodality imaging. Trends in Molecular Medicine 16 508-515. (doi:10.1016/j.molmed.2010.08.003)
83. Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, Miner JN & Diamond MI 2005 The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. PNAS 102 9802-9807. (doi:10.1073/pnas.0408819102)
84. Schroeder T 2008 Imaging stem-cell-driven regeneration in mammals. Nature 453 345-351. (doi:10.1038/nature07043)
85. Shankaranarayanan P, Rossin A, Khanwalkar H, Alvarez S, Alvarez R, Jacobson A, Nebbioso A, de Lera AR, Altucci L & Gronemeyer H 2009 Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO. Cancer Cell 16 220-231. (doi:10.1016/j.ccr.2009.07.029)
86. Snoeks TJ, Löwik CW & Kaijzel EL 2010 'In vivo' optical approaches to angiogenesis imaging. Angiogenesis 13 135-147. (doi:10.1007/s10456-010-9168-y)
87. Solomin L, Johansson CB, Zetterström RH, Bissonnette RP, Heyman RA, Olson L, Lendahl U, Frisén J & Perlmann T 1998 Retinoid-X receptor signalling in the developing spinal cord. Nature 395 398-402. (doi:10.1038/26515)
88. Spinelli AE, D'Ambrosio D, Calderan L, Marengo M, Sbarbati A & Boschi F 2010 Cerenkov radiation allows in vivo optical imaging of positron emitting radiotracers. Physics in Medicine and Biology 55 483-495. (doi:10.1088/0031- 9155/55/2/010)
89. Stanisić V, Lonard DM & O'Malley BW 2010 Modulation of steroid hormone receptor activity. Progress in Brain Research 181 153-176. (doi:10.1016/S0079-6123(08)81009-6)
90. Stell A, Belcredito S, Ramachandran B, Biserni A, Rando G, Ciana P & Maggi A 2007a Multimodality imaging: novel pharmacological applications of reporter systems. Quarterly Journal of Nuclear Medicine and Molecular Imaging 51 127-138. (Pubitemid 47071622)
91. Stell A, Biserni A, Della Torre S, Rando G, Ramachandran B, Ottobrini L, Lucignani G, Maggi A & Ciana P 2007b Cancer modeling: modern imaging applications in the generation of novel animal model systems to study cancer progression and therapy. International Journal of Biochemistry & Cell Biology 39 1288-1296. (doi:10.1016/j.biocel.2007.02.019)
92. Sun H, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, Douglas K & Shields AF 2005 Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. European Journal of Nuclear Medicine and Molecular Imaging 32 15-22. (doi:10.1007/s00259-004-1713-8)
93. Tian J, Bai J, Yan XP, Bao S, Li Y, Liang W & Yang X 2008 Multimodality molecular imaging. IEEE Engineering in Medicine and Biology Magazine 27 48-57. (doi:10.1109/MEMB.2008.923962)
94. Uhrbom L, Nerio E & Holland EC 2004 Dissecting tumour maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nature Medicine 10 1257-1260. (doi:10.1038/nm1120)
95. de Urquiza AM, Liu S, Sjöberg M, Zetterström RH, Griffiths W, Sjövall J & Perlmann T 2000 Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290 2140-2144. (doi:10.1126/science. 290.5499.2140)
96. de Vries EFJ, Rots MG & Hospers GAP 2007 Nuclear imaging of hormonal receptor status in breast cancer: a tool for guiding endocrine treatment and drug development. Current Cancer Drug Targets 7 510-519. (doi:10.2174/ 156800907781662301)
97. Weigel NL & Moore NL 2007 Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Molecular Endocrinology 21 2311-2319. (doi:10.1210/me.2007-0101)
98. Weihua Z, Lathe R, Warner M & Gustafsson J-A 2002 An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta, 17beta-diol, and CYP7B1, regulates prostate growth. PNAS 99 13589-13594. (doi:10.1073/pnas. 162477299)
99. Weissleder R & Pittet MJ 2008 Imaging in the era of molecular oncology. Nature 452 580-589. (doi:10.1038/nature06917)
100. William WN, Heymach JV, Kim ES & Lippman SM 2009 Molecular targets for cancer chemoprevention. Nature Reviews. Drug Discovery 8 213-225. (doi:10.1038/nrd2663)
101. Willmann JK, Paulmurugan R, Chen K, Gheysens O, Rodriguez-Porcel M, Lutz AM, Chen IY, Chen X & Gambhir SS 2008 US imaging of tumour angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 246 508-518. (doi:10.1148/radiol.2462070536)
102. Ye X, Han SJ, Tsai SY, DeMayo FJ, Xu J, Tsai M-J & O'Malley BW 2005 Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice. PNAS 102 9487-9492. (doi:10.1073/pnas.0503577102)
103. Zhao X, van Steenbrugge GJ & Schröder FH 1992 Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells LNCaP to tumour necrosis factor. Urological Research 20 193-197. (doi:10.1007/BF00299716)
104. Zielinski JE, Larner JM, Hoffer PB & Hochberg RB 1989 The synthesis of 11 beta-methoxy-[16 alpha-123I] iodoestradiol and its interaction with the estrogen receptor in vivo and in vitro. Journal of Nuclear Medicine 30 209-215. (Pubitemid 19048516)
105. Zilli M, Grassadonia A, Tinari N, Giacobbe AD, Gildetti S, Giampietro J, Natoli C, Iacobelli S & per la Bio-Oncologia (CINBO), C. I. N 2009 Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. Biochimica et Biophysica Acta 1795 62-81. (doi:10.1016/j.bbcan. 2008.08.003)